In vitro and in vivo pharmacological characterization of the synthetic opioid MT-45.
Aggression
/ drug effects
Analgesics, Opioid
/ antagonists & inhibitors
Animals
CHO Cells
Cricetinae
Cricetulus
Dose-Response Relationship, Drug
Hemodynamics
/ drug effects
Hot Temperature
Humans
Mice
Morphine
/ antagonists & inhibitors
Motor Activity
/ drug effects
Muscle Strength
/ drug effects
Naloxone
/ pharmacology
Narcotic Antagonists
/ pharmacology
Pain Measurement
/ drug effects
Physical Stimulation
Piperazines
/ antagonists & inhibitors
Receptors, Opioid
/ drug effects
Respiration
/ drug effects
Sensation
/ drug effects
DMR assay
MT-45
Morphine
Naloxone
Novel psychoactive substances
Synthetic opioids
Journal
Neuropharmacology
ISSN: 1873-7064
Titre abrégé: Neuropharmacology
Pays: England
ID NLM: 0236217
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
23
12
2019
revised:
31
03
2020
accepted:
15
04
2020
pubmed:
29
4
2020
medline:
29
6
2021
entrez:
29
4
2020
Statut:
ppublish
Résumé
MT-45 is a synthetic opioid that was developed in the 1970s as an analgesic compound. However, in recent years MT-45 has been associated with multiple deaths in Europe and has been included in the class of novel psychoactive substances known as novel synthetic opioids (NSOs). Little is known about the pharmaco-toxicological effects of MT-45. Therefore, we used a dynamic mass redistribution (DMR) assay to investigate the pharmacodynamic profile of this NSO in vitro compared with morphine. We then used in vivo studies to investigate the effect of the acute systemic administration of MT-45 (0.01-15 mg/kg i.p.) on motor and sensorimotor (visual, acoustic and tactile) responses, mechanical and thermal analgesia, muscle strength and body temperature in CD-1 male mice. Higher doses of MT-45 (6-30 mg/kg i.p.) were used to investigate cardiorespiratory changes (heart rate, respiratory rate, SpO
Identifiants
pubmed: 32344007
pii: S0028-3908(20)30178-7
doi: 10.1016/j.neuropharm.2020.108110
pii:
doi:
Substances chimiques
Analgesics, Opioid
0
Narcotic Antagonists
0
Piperazines
0
Receptors, Opioid
0
Naloxone
36B82AMQ7N
(+,-)-1-cyclohexyl-4-(1,2-diphenylethyl)piperazine
52694-55-0
Morphine
76I7G6D29C
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108110Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The Authors declare no conflict of interest.